Remdesivir remains a controversial treatment for COVID-19.1 ACTT-1 was an international study funded by the US National Institutes of Health that showed reduced time to recovery with remdesivir (its updated primary endpoint) and improvement on an eight-point ordinal scale (the original primary endpoint).2 Mostly based on this trial, the US Food and Drug Administration (FDA) approved the emergency use of remdesivir for patients with COVID-19.3 This decision was widely contested because of the paucity of clinically significant benefits on mortality. Afterwards, two additional, large clinical trials—WHO's Solidarity and the DisCoVeRy trial—showed a neutral effect on mortality without improvement in time to discharge.1, 4
Hence, the question arises of which of these three trials we should listen to. Their study designs were essentially the same, but their circumstances were entirely different. The ACTT-1 preliminary report was published in May, 2020—before the RECOVERY trial reported that dexamethasone reduced mortality in patients hospitalised with COVID-19 in July, 2020.2, 5 Furthermore, it reported use of corticosteroids in only 23% of patients, with unknown indication.2 By contrast, substantial parts of the study periods of the Solidarity and DisCoVeRy trials occurred after dexamethasone had become the standard of care. And although Solidarity mentions use of corticosteroids in almost 50% of participants (also without specification), DisCoVeRy mentions dexamethasone specifically and that almost 40% of participants received it.1, 4 Thus, it is reasonable to assume that a large proportion of the corticosteroids used in these trials were prescribed because of the results reported in RECOVERY, which was not the case for corticosteroid use in ACTT-1. Consequently, the standard of care was substantially different between ACTT-1 and Solidarity or DisCoVeRy. Because dexamethasone is now the standard of care, the treatment regimen of ACTT-1 is not compatible with the current treatment of patients admitted to hospital due to COVID-19.
In summary, the results of ACTT-1 are simply not applicable to present-day standard of care and Solidarity and DisCoVeRy should be given more weight when considering the addition of remdesivir to the treatment of patients in hospital due to COVID-19.
We declare no competing interests.
References
- 1.Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2021 doi: 10.1016/S1473-3099(21)00485-0. published online Sept 14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of COVID-19—final report. N Engl J Med. 2020;383:1813–1826. doi: 10.1056/NEJMoa2007764. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.US Food and Drug Administration FDA approves first treatment for COVID-19. Oct 22, 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19
- 4.Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for COVID-19—interim WHO SOLIDARITY trial results. N Engl J Med. 2021;384:497–511. doi: 10.1056/NEJMoa2023184. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384:693–704. doi: 10.1056/NEJMoa2021436. [DOI] [PMC free article] [PubMed] [Google Scholar]